This study is collecting tumor samples and health information from people with certain cancers, including head and neck, lung, and urothelial carcinoma (bladder cancer). Researchers are using these samples to develop and test a diagnostic tool called OncoPrism™. This tool looks at specific markers (PD-1, PD-L1) in tumor tissue to understand how well people might respond to PD-1/PD-L1 inhibitor treatments. The goal is to see how well these markers predict a response to treatment after 6 months. The study is currently unclear on its recruitment status.

Study design

This is an observational study planning to enroll 1650 participants. It collects de-identified tumor samples and clinical data.

What's involved

You would provide consent for your tumor samples and health information to be used. The study does not require extra biopsies; standard-of-care biopsies taken before immunotherapy are used.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint measures PD-L1/PD-1 inhibitor response at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.